Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Year Fiscal 2021 Fourth quarter revenue grew 38% year-over-year to $46.3 million Full year 2021 revenue grew 40% to $166.2 million Framingham, M

Definitive Healthcare Reports Financial Results for Fourth Quarter

and Full Year Fiscal 2021

Fourth quarter revenue grew 38% year-over-year to $46.3 million

Full year 2021 revenue grew 40% to $166.2 million

Framingham, MA (February 23, 2022) Definitive Healthcare Corp. ( Definitive Healthcare ) (Nasdaq: DH), an industry leader in

healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2021.

Financial Highlights:

Full Year 2021 Financial Highlights:

2021 was a transformational year for Definitive Healthcare, and we ended the year with strong

financial results that reflect the significant momentum that we have across all parts of our business, said Jason Krantz, CEO and Founder of Definitive Healthcare. Our innovation flywheel continues to spin, as we expand our data set and

deliver new analytics that address our customers most pressing challenges. Whether it s our new Latitude Reporting product, or our recent acquisition of Analytical Wizards, we continue to deliver the commercial intelligence that our

customers need to navigate and sell into the large and complex healthcare market.

Recent Business and Operating Highlights:

In the fourth quarter, Definitive

Healthcare continued to grow its enterprise client base, ending the year with 417 Enterprise customers, defined as those customers with over one hundred thousand dollars in annual recurring revenue. Significant customer wins included:

In the fourth quarter of 2021, the company launched Latitude Reporting, a new product that allows users to build in real-time custom patient cohorts targeting

specific disease states. With Latitude Reporting, users can quickly perform iterative analysis on real-world data to gain actionable intelligence that accelerates their

go-to-market strategy.

Also in the fourth quarter, the company added

Asian expert data to its Monocl ExpertInsight product, giving medical affairs professionals access to more than 11 million worldwide expert profiles.

Finally, the company recently acquired Analytical Wizards, an industry leader in delivering technology-enabled advanced analytics to life science companies.

Analytical Wizards is used by six of the top ten global pharmaceutical companies, as ranked by revenue, and four of the top seven global biotech companies, as ranked by market value. With the Analytical Wizards software as a solution

( SaaS ) product line, customers can combine data from multiple sources, including Definitive Healthcare, and then run detailed analytics on-demand to gain new intelligence on product planning,

marketing optimization, and product performance. Founded in 2015, Analytical Wizards has more than 100 employees with offices in the US and Bangalore.

Based on information as of

February 23, 2022, the Company is issuing the following financial guidance.

Conference Call Information

Definitive Healthcare will host a conference call today, February 23, 2022, at 5:00 p.m. (Eastern Time) to discuss the Company s financial results

and current business outlook. To access the call, dial (877) 407-3982 (domestic) or (201) 493-6780 (international). The conference ID number is 13726682. Shortly after

the conclusion of the call, a replay of this conference call will be available through March 9, 2022 at (844) 512-2921 (domestic) or (412) 317-6671 (international).

The replay passcode is 13726682. A live audio webcast of the event will be available on the Definitive Healthcare s Investor Relations website at https://ir.definitivehc.com/.

About Definitive Healthcare

At Definitive Healthcare, our passion is to transform data, analytics and expertise into healthcare commercial intelligence. We help clients uncover the right

markets, opportunities and people, so they can shape tomorrow s healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next.

Forward-Looking Statements

This press release may

include forward-looking statements that reflect our current views with respect to future events and financial performance. Such statements are provided under the safe harbor protection of the Private Securities Litigation Reform Act of

1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by words or phrases written in the future tense and/or preceded by words such as likely,

should, may, anticipates, intends, plans, seeks, believes, estimates, expects or similar words or variations thereof, or the negative

thereof, references to future periods, or by the inclusion of forecasts or projections, but these terms are not the exclusive means of identifying such statements. Examples of forward-looking statements include, but are not limited to, statements we

make regarding our outlook, financial guidance, the market, industry and macroeconomic environment, our business, growth strategies, product development efforts and future expenses, and statements reflecting our expectations about our ability to

execute on our strategic plans, achieve future growth and profitability and achieve our financial goals.

Forward-looking statements in this press

release are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties,

risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially

from those in the forward-looking statements include the following: an outbreak of disease, global or localized health pandemic or epidemic, or the fear of such an event (such as the COVID-19 global pandemic),

including the global economic uncertainty and measures taken in response; the short- and long-

term effects of the COVID-19 global pandemic, including the pace of recovery or any future resurgence; our inability to generate substantially all of our

revenue and cash flows from sales of subscriptions to our platform and any decline in demand for our platform and the data we offer; the competitiveness of the market in which we operate and our ability to compete effectively; the failure to

maintain and improve our platform, or develop new modules or insights for healthcare commercial intelligence; the inability to obtain and maintain accurate, comprehensive or reliable data, which could result in reduced demand for our platform; the

risk that our recent growth rates may not be indicative of our future growth; the inability to achieve or sustain profitability in the future compared to historical levels as we increase investments in our business; the loss of our access to our

data providers, which could negatively impact our platform; the failure to respond to advances in healthcare commercial intelligence; an inability to attract new customers and expand subscriptions of current customers; the risk of cyber-attacks and

security vulnerabilities; and if our security measures are breached or unauthorized access to data is otherwise obtained, our platform may be perceived as not being secure, customers may reduce the use of or stop using our platform, and we may incur

significant liabilities.

For additional discussion of factors that could impact our operational and financial results, refer to our Quarterly

Report on Form 10-Q for the three months ended September 30, 2021 and our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 that will be

filed following this earnings release, and our subsequent SEC filings, which are or will be available on the Investor Relations page of our website at ir.definitivehc.com and on the SEC website at www.sec.gov.

Additional factors or events that could cause our actual performance to differ from these forward-looking statements may emerge from time to time, and it

is not possible for us to predict all of them. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual financial condition, results of operations, future performance and business

may vary in material respects from the performance projected in these forward-looking statements.

Any forward-looking statement made by us speaks

only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Definitive Healthcare intends to use its website as a distribution channel of material company information. Financial and other important information

regarding the Company is routinely posted on and accessible through the Company s website at https://www.definitivehc.com/. Accordingly, you should monitor the investor relations portion of our website at

https://ir.definitivehc.com/ in addition to following our press releases, SEC filings, and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll

your email address by visiting the Email Alerts section of our investor relations page at https://ir.definitivehc.com/.

A Reconciliation of GAAP to Non-GAAP results has been provided in the financial statement

tables included at the end of this press release. An explanation of these measures is also included below under the heading Non-GAAP Financial Measures.

Non-GAAP Financial Measures

We have presented supplemental non-GAAP financial measures as part of this earnings release. We

believe that these supplemental non-GAAP financial measures are useful to investors because they allow for an evaluation of the company with a focus on the performance of its core operations, including

providing meaningful comparisons of financial results to historical periods and to the financial results of peer and competitor companies.

We refer to Unlevered Free Cash Flow, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit, Adjusted Gross Margin, Adjusted

Operating Income and Adjusted Net Income as non-GAAP financial measures. These non-GAAP financial measures are not prepared in accordance with generally accepted

accounting principles in the U.S., ( GAAP ). These are supplemental financial measures of our performance and should not be considered substitutes for net (loss) income, gross profit or any other measure derived in accordance with

We define Unlevered Free Cash Flow as net cash provided from operating activities less purchases of property and equipment

and other assets, plus cash interest expense, cash payments related to transaction related expenses and cash payments related to other non-recurring items. Unlevered Free Cash Flow does not represent residual

cash flow available for discretionary expenditures since, among other things, we have mandatory debt service requirements.

We define EBITDA as earnings before debt-related costs, including interest expense, net

and loss on extinguishment of debt, income taxes and depreciation and amortization. Adjusted EBITDA is defined as EBITDA adjusted to exclude certain items of a significant or unusual nature, including other income and expense, equity-based

compensation, transaction expenses and other non-recurring expenses. Adjusted EBITDA Margin is defined as Adjusted EBITDA as a percentage of revenue. Adjusted EBITDA and Adjusted EBITDA Margin are key metrics

used by management and our board of directors to assess the profitability of our operations. We believe that Adjusted EBITDA and Adjusted EBITDA Margin provide useful measures to investors to assess our operating performance because these metrics

eliminate non-recurring and unusual items and non-cash expenses, which we do not consider indicative of ongoing operational performance. We believe that these metrics

are helpful to investors in measuring the profitability of our operations on a consolidated level.

We define Adjusted Gross Profit

as revenue less cost of revenue (excluding acquisition-related depreciation and amortization and equity compensation costs) and Adjusted Gross Margin means Adjusted Gross Profit as a percentage of revenue. Adjusted Gross Profit differs from gross

profit, in that gross profit includes acquisition-related depreciation and amortization expense and equity compensation costs. Adjusted Gross Profit and Adjusted Gross Margin are key metrics used by management and our board of directors to assess

our operations. We exclude acquisition-related depreciation and amortization expenses as they have no direct correlation to the cost of operating our business on an ongoing basis. A small quantity of equity-based compensation is included in cost of

revenue in accordance with GAAP but is excluded from our Adjusted Gross Profit calculations due to its non-cash nature.

We define Adjusted Operating Income as income (loss) from operations plus acquisition related amortization, equity-based compensation,

transaction expenses and other non-recurring expenses.

We define Adjusted Net Income as

Adjusted Operating Income less recurring income taxes, interest expense, net, foreign currency loss (gain) and including the incremental tax effects of adjustments to arrive at Adjusted Operating Income. We define Adjusted Net Income Per Diluted

Share as Adjusted Net Income divided by diluted outstanding shares.

Our use of these non-GAAP terms may vary from the

use of similar terms by other companies in our industry and accordingly may not be comparable to similarly titled measures used by other companies and are not measures of performance calculated in accordance with GAAP. Our presentation of these non-GAAP financial measures are intended as supplemental measures of our performance that are not required by, or presented in accordance with, GAAP. These non-GAAP financial

measures should not be considered as alternatives to (loss) income from operations, net (loss) income, gross profit, earnings per share or any other performance measures derived in accordance with GAAP, or as measures of operating cash flows or

We do not provide a quantitative reconciliation of the forward-looking non-GAAP

financial measures included in this press release to the most directly comparable GAAP measures due to the high variability and difficulty to predict certain items excluded from these non-GAAP financial

measures; in particular, the effects of stock-based compensation expense, taxes and amounts under the exchange tax receivable agreement, deferred tax assets and deferred tax liabilities, and restructuring and transaction expenses. We expect the